News & insights

Be a part of our exciting journey. Here you will find CLS’s, newsletters, events, films, media coverage and analyzes.

21 December, 2022

Christmas greeting from CLS - We wish you all a very Happy Holiday season and look forward to a tremendous 2023!

At CLS we can look back on an exciting year where we have made significant progress towards our vision that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to traditional surgery and, in the longer term, as a complementary systemic treatment of metastasized cancer.

Read more
28 November, 2022

Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Read more
2 November, 2022

Interview with our CTO and VP Clinical Affairs – How CLS contributes to better treatment of Prostate Cancer

Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.

Read more
1 November, 2022

CLS Supports Movember - Introduction by CEO Dan J. Mogren

CEO Dan J. Mogren introduces our support for Movember. This annual campaign is all about raising awareness around male health, and specifically around prostate cancer. It is one of the most common cancer forms among men, but more can be done to spread knowledge about the disease.

Read more
17 October, 2022

Demonstration of Targeted Focal Therapy with Fusion-guided Laser Ablation by Dr. Fernando J. Bianco

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

Read more
26 September, 2022

CLS receives FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery

We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!

Read more
22 September, 2022

CLS Americas & Focalyx Present Integrated Fusion-Guided Focal Laser Ablation Solution at FOCAL 2022 Conference

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

Read more
21 April, 2022

CLS Americas and URN Announce First Patient Treated in Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”

CLS Americas today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study.

Read more
5 April, 2022

CLS Americas Inc. and URN Announce Clinical Study “Targeted MRI/US Fusion Transperineal Laser Ablation of Low to Intermediate Risk Prostate Cancer”

Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Read more
18 February, 2022

Radboud University Medical Center (Nijmegen, NL) has initiated a clinical trial using the CLS TRANBERG® products for patients with prostate cancer​

Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.

Read more

Sign up for our newsletter

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US